



AUG 02 2006

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office						Atty. Docket No. 51400-B/JPW/AJM/MML	Serial No. 09/940,727
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)								Applicant: Donald W. Landry	
								Filing Date August 28, 2001	Group 1652
<b>U.S. PATENT DOCUMENTS</b>									
Examiner Initials <i>DL</i>		Document Number 3 9 7 5 2 3 7			Date 8/17/76	Name Rubenstein et al.	Class 195	Subclass 63	Filing Date if Appropriate
<b>FOREIGN PATENT DOCUMENTS</b>									
<i>DL</i>		Document Number WO 9 3 2 0 0 7 6			Date 10/14/93	Country PCT	Class	Subclass	Translation
									Yes
									No
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>									
<i>DL</i>		Basmadjian et al. (1995) Generation of polyclonal catalytic antibodies against cocaine using transition state analogs of cocaine conjugated to Diphtheria toxoid, Chem. Pharm. Bull. 43(11):1995-2011, <i>1902-1911</i>							
<i>DL</i>		Landry, Donald W. (1995) Anti-cocaine catalytic antibodies: A novel approach to addiction, Abstracts of Papers Am. Chem. Soc. 209, ANYL 19, Abstract No. XP000992924; and							
<i>DL</i>		Landry et al. (1997) Anti-cocaine catalytic antibodies: A novel approach to the problem of addiction, J. Addict. Dis. 16(3):1-17.							
EXAMINER <i>Donald W. Landry</i>		DATE CONSIDERED <i>2/9/05</i>							
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>									